An update in Mesothelioma and Thymoma Management ASCO 2014 update Khalid Alsaleh King Saud University FRCPC, FACP, MSc
Mesothelioma
Outline
Outline Presented By Marjorie Zauderer at 2014 ASCO Annual Meeting
Mesothelioma Treatment Algorithm Presented By Marjorie Zauderer at 2014 ASCO Annual Meeting
P/D v. EPP: Less Surgery May Be Better Presented By Marjorie Zauderer at 2014 ASCO Annual Meeting
Evaluation of Mesothelioma in a Phase III Study of ALIMTA with CISplatin: 3 Month Survival Advantage Presented By Marjorie Zauderer at 2014 ASCO Annual Meeting
Rare Responses with 2nd Line Chemotherapy Presented By Marjorie Zauderer at 2014 ASCO Annual Meeting
Outline Presented By Marjorie Zauderer at 2014 ASCO Annual Meeting
Three Common Somatic Aberrations in Mesothelioma: CDKN2A, NF2, BAP1 Presented By Marjorie Zauderer at 2014 ASCO Annual Meeting
Outline Presented By Marjorie Zauderer at 2014 ASCO Annual Meeting
Partial List of Ongoing Clinical Trials Presented By Marjorie Zauderer at 2014 ASCO Annual Meeting
mtor/pi3k Signaling Pathway Presented By Marjorie Zauderer at 2014 ASCO Annual Meeting
Response to Dual PI3K/mTOR Inhibition with GDC0980 Presented By Marjorie Zauderer at 2014 ASCO Annual Meeting
FAK Inhibition Effective with Merlin Loss Presented By Marjorie Zauderer at 2014 ASCO Annual Meeting
Randomized Phase II Study of Defactinib Maintenance (ASCO #TPS7611) Presented By Marjorie Zauderer at 2014 ASCO Annual Meeting
CTLA-4 Therapy in Mesothelioma Presented By Marjorie Zauderer at 2014 ASCO Annual Meeting
Ongoing Randomized Phase II Tremelimumab Trial Presented By Marjorie Zauderer at 2014 ASCO Annual Meeting
Mesothelin as a Therapeutic Target Presented By Marjorie Zauderer at 2014 ASCO Annual Meeting
CRS-207 Stimulates Cellular Immunity to Mesothelin (ASCO #7532) Presented By Marjorie Zauderer at 2014 ASCO Annual Meeting
Response to Anti-Mesothelin Immunotoxin SS1P and Immune Suppression Presented By Marjorie Zauderer at 2014 ASCO Annual Meeting
Conclusions/Future Directions Presented By Marjorie Zauderer at 2014 ASCO Annual Meeting
Thymoma
Outline/Learning Objectives<br />
Thymic Epithelial Tumors
Thymomas - General Characteristics
Incidence
The incidence of Thymic Malignancy is increasing
PubMed Literature Search Thymoma<br />January 1989-December 2009 (n=1991 papers)
ITMIG
International Thymic Malignancies Interest Group (ITMIG) Mission
ITMIG Membership 10-2013
ITMIG Status
Slide 14
Slide 15
ITMIG Retrospective Data-Map
Slide 17
Slide 18
Slide 19
Slide 20
Staging
Slide 22
Prognostic Value of Masaoka Stage
Prognostic Value of Masoaka Stage
ITMIG-IASLC Stage Classification Project
ITMIG-IASLC Stage Classification Proposal
ITMIG Node Map
Histological Classification
Slide 30
WHO 2004 histological classification of TETs
WHO classification: survival implications
Histologic Classification
Molecular Biology
Slide 35
Slide 36
Genetic Alterations
Slide 38
Gene Signatures
Slide 40
Slide 41
Gene signatures
Treatment
Thymoma - 5-year survival
Treatment - Early Stage Thymic Malignancy
Treatment - Locally Advanced
Slide 47
Thymoma - surgery
Five year Survival: Stage III/IV
Slide 50
Thymoma - radiotherapy
Slide 52
Prospective Chemotherapy Trials
Treatment
Thymic Malignancies Treatment Summary
Challenges in research
Targeted Therapies
Genetic Abnormalities in Thymic Malignancies
Targeted therapies in Thymic Malignancies
Sunitinib in TETs: Best response to treatment
Custom Trial
Slide 62
Slide 63
Epigenetic Gene mutations in TC
Slide 65
Conclusions